Exscientia (NASDAQ:EXAI - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.05), Zacks reports. Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. The firm had revenue of $5.60 million during the quarter.
Exscientia Price Performance
Exscientia stock traded up $0.02 during mid-day trading on Friday, reaching $5.32. 535,197 shares of the company's stock traded hands, compared to its average volume of 634,051. The company has a market cap of $643.12 million, a price-to-earnings ratio of -4.06 and a beta of 0.85. The stock has a 50 day moving average of $5.21 and a two-hundred day moving average of $5.39. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.05. Exscientia has a 12-month low of $3.80 and a 12-month high of $7.91.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. TD Cowen reissued a "hold" rating on shares of Exscientia in a report on Friday, August 9th. Barclays reissued an "equal weight" rating and issued a $5.00 target price on shares of Exscientia in a report on Tuesday, August 13th. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $7.00 target price on shares of Exscientia in a report on Monday, April 22nd.
View Our Latest Stock Analysis on Exscientia
Exscientia Company Profile
(
Get Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
Further Reading
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
